[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627260":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":35,"locations":41,"responsibleParty":168,"collaborators":11,"id":170,"slug":171,"hasResults":172,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":11,"eligibilityCriteria":176,"healthyVolunteers":172,"sex":177,"minAge":178,"maxAge":11,"enrollmentInfo":179,"targetDuration":11,"studyType":182,"phases":183,"briefSummary":185,"conditions":186,"keywords":11,"overallStatus":44,"whyStopped":11,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":199},{"fullName":5,"class":6},"Oncolytics Biotech","INDUSTRY",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A","EXPERIMENTAL",null,[13,14,15],"Drug: Bevacizumab","Drug: FOLFIRI","Drug: Pelareorep",{"label":17,"type":10,"description":11,"interventionNames":18},"Arm B",[13,14],[20,27,31],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Bevacizumab","Bevacizumab (5 mg\u002Fkg) IV infusion",[9,17],[26],"Avastin",{"type":21,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"FOLFIRI","irinotecan (180mg\u002Fm2), leucovorin 400 mg\u002Fm2 ± 5-FU (400 mg\u002Fm2) IV infusion",[9,17],{"type":21,"name":32,"description":33,"armGroupLabels":34,"otherNames":11},"Pelareorep","pelareorep 4.5 x 10\\^10 TCID50 IV infusion",[9],[36],{"name":37,"role":38,"phone":39,"phoneExt":11,"email":40},"Name: Reference Study ID Number: REO 033","CONTACT","+1 (858) 247- 7829","REO-033@oncolytics.ca",[42,56,66,75,84,93,99,108,118,129,139,149,158],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":11},"Central Alabama Research","RECRUITING","Homewood","Alabama","35209","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-86.80082,33.47177,{"lat":54,"lon":53},{"facility":57,"status":44,"city":58,"state":59,"zip":60,"country":48,"countryCode":49,"cosmosGeoPoint":61,"geoPoint":65,"contacts":11},"Clinical Research Advisors (Beverly Hills)","Beverly Hills","California","90211",{"type":51,"coordinates":62},[63,64],-118.40036,34.07362,{"lat":64,"lon":63},{"facility":67,"status":44,"city":68,"state":59,"zip":69,"country":48,"countryCode":49,"cosmosGeoPoint":70,"geoPoint":74,"contacts":11},"Clinical Research Advisors (Encino)","Encino","91316",{"type":51,"coordinates":71},[72,73],-118.50119,34.15917,{"lat":73,"lon":72},{"facility":76,"status":44,"city":77,"state":59,"zip":78,"country":48,"countryCode":49,"cosmosGeoPoint":79,"geoPoint":83,"contacts":11},"Clinical Research Advisors (Korea Town)","Koreatown","90020",{"type":51,"coordinates":80},[81,82],-118.30091,34.05779,{"lat":82,"lon":81},{"facility":85,"status":44,"city":86,"state":59,"zip":87,"country":48,"countryCode":49,"cosmosGeoPoint":88,"geoPoint":92,"contacts":11},"Clinical Research Advisors (Downtown LA)","Los Angeles","90033",{"type":51,"coordinates":89},[90,91],-118.24368,34.05223,{"lat":91,"lon":90},{"facility":94,"status":44,"city":86,"state":59,"zip":95,"country":48,"countryCode":49,"cosmosGeoPoint":96,"geoPoint":98,"contacts":11},"Clinical Research Advisors (West Hollywood)","90048",{"type":51,"coordinates":97},[90,91],{"lat":91,"lon":90},{"facility":100,"status":44,"city":101,"state":59,"zip":102,"country":48,"countryCode":49,"cosmosGeoPoint":103,"geoPoint":107,"contacts":11},"Clinical Research Advisors (West Covina)","West Covina","91790",{"type":51,"coordinates":104},[105,106],-117.93895,34.06862,{"lat":106,"lon":105},{"facility":109,"status":44,"city":110,"state":111,"zip":112,"country":48,"countryCode":49,"cosmosGeoPoint":113,"geoPoint":117,"contacts":11},"Emory Winship Cancer Institute","Atlanta","Georgia","30302",{"type":51,"coordinates":114},[115,116],-84.38798,33.749,{"lat":116,"lon":115},{"facility":119,"status":120,"city":121,"state":122,"zip":123,"country":48,"countryCode":49,"cosmosGeoPoint":124,"geoPoint":128,"contacts":11},"Community Health Network","NOT_YET_RECRUITING","Indianapolis","Indiana","46250",{"type":51,"coordinates":125},[126,127],-86.15804,39.76838,{"lat":127,"lon":126},{"facility":130,"status":120,"city":131,"state":132,"zip":133,"country":48,"countryCode":49,"cosmosGeoPoint":134,"geoPoint":138,"contacts":11},"Washington University School of Medicine","St Louis","Missouri","63110",{"type":51,"coordinates":135},[136,137],-90.19789,38.62727,{"lat":137,"lon":136},{"facility":140,"status":44,"city":141,"state":142,"zip":143,"country":48,"countryCode":49,"cosmosGeoPoint":144,"geoPoint":148,"contacts":11},"Summit Health Cancer Center","Florham Park","New Jersey","07932",{"type":51,"coordinates":145},[146,147],-74.38821,40.78788,{"lat":147,"lon":146},{"facility":150,"status":44,"city":151,"state":142,"zip":152,"country":48,"countryCode":49,"cosmosGeoPoint":153,"geoPoint":157,"contacts":11},"Rutgers Cancer Institute","New Brunswick","08901",{"type":51,"coordinates":154},[155,156],-74.45182,40.48622,{"lat":156,"lon":155},{"facility":159,"status":44,"city":160,"state":161,"zip":162,"country":48,"countryCode":49,"cosmosGeoPoint":163,"geoPoint":167,"contacts":11},"Gabrail Cancer Center","Canton","Ohio","44718",{"type":51,"coordinates":164},[165,166],-81.37845,40.79895,{"lat":166,"lon":165},{"type":169,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100627260","phase-2-folfiri-and-bevacizumab-with-or-without-pelareorep-for-second-line-treatment-of-metastatic-ras-mutated-microsatellite-stable-colorectal-cancer-100627260",false,"NCT07446322","FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer","An Open-Label, Randomized, Multicentre, Phase 2 Study of FOLFIRI + Bevacizumab + Pelareorep vs. FOLFIRI + Bevacizumab for the Second-Line Treatment of Metastatic, RAS-mutated, Microsatellite-Stable (MSS) Colorectal Cancer","Inclusion Criteria:\n\n* Histologically confirmed cancer of the colon or rectum with documented metastasis\n* Measurable disease per RECIST v. 1.1\n* Not candidates for curative surgery or curative radiation\n* Progressed on, or been intolerant to, a first-line, oxaliplatin-based chemotherapy regimen in the metastatic setting or relapsed within 6 months of completing adjuvant oxaliplatin\n* Considered medically eligible to receive standard of care (SOC) FOLFIRI with bevacizumab\n* Non-microsatellite instability high or non-deficient mismatch repair (non-MSI-H\u002Fnon dMMR) tumor status per a standard local testing method\n* Tumor confirmed to harbor a known RAS mutation per a standard local testing method\n* ECOG performance status of 0 or 1\n* Patients must have adequate hematological, renal, and hepatic function\n* Female patients of childbearing potential must have a negative pregnancy test\n* Life expectancy of at least 6 months\n\nExclusion Criteria:\n\n* Undergone systemic chemotherapy, radiotherapy, or surgery, \\\u003C4 weeks before study treatment\n* Ongoing AEs of Grade ≥2 that are related to anti-cancer treatment\n* Prior treatment with irinotecan\n* Symptomatic brain metastases\n* Active autoimmune disease\n* Receiving immunosuppressive or myelosuppressive medications\n* Active, uncontrolled infections\n* Known HIV infection or active hepatitis B or C that requires anti-viral treatment\n* History of another primary cancer within the last 3 years except for non-melanoma skin cancer, early-stage prostate cancer, or curatively treated cervical carcinoma in-situ\n* History of allergy or known hypersensitivity to any of the study drugs, study drug classes,\n* Uncontrolled or severe cardiac disease\n* Received any vaccine within 28 days prior to first study treatment","ALL","18 Years",{"count":180,"type":181},60,"ESTIMATED","INTERVENTIONAL",[184],"PHASE2","This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs. FOLFIRI + bevacizumab in patients with RAS-mutated, MSS mCRC who have progressed after one prior line of oxaliplatin-based therapy.",[187,188,189],"Ras-mutated Metastatic Colorectal Cancer","mCRC","MSS Metastatic Colorectal Cancer","2026-08-19",{"date":192,"type":193},"2026-08-20","ACTUAL",{"date":195,"type":193},"2026-04-30",{"date":197,"type":181},"2030-04-30",{"name":5,"class":6},13]